RFK Jr. proposes FDA look the other way on unproven peptides, report says
Summary
Health Secretary Robert F. Kennedy Jr. is leading the FDA to consider easing rules on certain peptide drugs that are popular but not proven safe or effective. This move could allow these drugs to be more readily available through specialty pharmacies, even though FDA scientists have warned about their risks.Key Facts
- The FDA submitted a plan called “Interim Access Policy” to the White House to allow less strict enforcement on some peptide drugs.
- Peptides are injectable drugs with claims to boost energy, improve looks, or heal injuries, but these claims lack solid scientific proof.
- In 2023, FDA scientists removed 12 peptides from the list of drugs allowed to be made by compounding pharmacies due to safety and effectiveness concerns.
- Kennedy appointed new members to the FDA advisory panel, many of whom have connections to peptide businesses.
- The panel recommended putting some peptides back on the approved compounding list, despite FDA staff objections.
- Officially approving peptides again could take years and require public input, so the enforcement discretion may speed up access.
- Some groups, like the Center for Science in the Public Interest, oppose this change, warning it may put consumers at risk.
- Kennedy has expressed support for peptides and aims to reduce FDA restrictions on them.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
